GLP1R and atherosclerosis: Recent guidelines recommend that GLP-1 receptor agonists (GLP-1 RA) or SGLT2 inhibitors (SGLT2i) with proven benefits should be used in established atherosclerotic cardiovascular disease (ASCVD) to reduce major adverse cardiovascular events.